Passive Immunity Trial for Our Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults

Wesley H. Self, Thomas G. Stewart, Allison P. Wheeler, Wissam El Atrouni, Amanda J. Bistran-Hall, Jonathan D. Casey, Vince D. Cataldo, James D. Chappell, Claudia S. Cohn, Jessica B. Collins, Mark R. Denison, Marjolein de Wit, Sheri L. Dixon, Abhijit Duggal, Terri L. Edwards, Magali J. Fontaine, Adit A. Ginde, Michelle S. Harkins, Thelma Harrington, Estelle S. Harris, Daanish Hoda, Tina S. Ipe, Stuti J. Jaiswal, Nicholas J. Johnson, Alan E. Jones, Maryrose Laguio-Vila, Christopher J. Lindsell, Jason Mallada, Manoj J. Mammen, Ryan A. Metcalf, Elizabeth A. Middleton, Simon Mucha, Hollis R. O’Neal Jr, Sonal R. Pannu, Jill M. Pulley, Xian Qiao, Jay S. Raval, Jillian P. Rhoads, Harry Schrager, Carl Shanholtz, Nathan I. Shapiro, Stephen J. Schrantz, Isaac Thomsen, Krista K. Vermillion, Gordon R. Bernard, Todd W. Rice and For the Passive Immunity Trial for Our Nation (PassITON) Investigators

Abstract

Background: Convalescent plasma is being used widely as a treatment for coronavirus disease 2019 (COVID-19). However, the clinical efficacy of COVID-19 convalescent plasma is unclear.

Methods: The Passive Immunity Trial for Our Nation (PassITON) is a multicenter, placebo-controlled, blinded, randomized clinical trial being conducted in the USA to provide high-quality evidence on the efficacy of COVID-19 convalescent plasma as a treatment for adults hospitalized with symptomatic disease. Adults hospitalized with COVID-19 with respiratory symptoms for less than 14 days are eligible. Enrolled patients are randomized in a 1:1 ratio to 1 unit (200–399 mL) of COVID-19 convalescent plasma that has demonstrated neutralizing function using a SARS-CoV-2 chimeric virus neutralization assay. Study treatments are administered in a blinded fashion and patients are followed for 28 days. The primary outcome is clinical status 14 days after study treatment as measured on a 7-
Background
Since emerging in late 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global health crisis [1]. The disease caused by SARS-CoV-2 infection, coronavirus disease 19 (COVID-19), has caused over 2.1 million deaths worldwide through January 2021 [2]. Despite vast ongoing efforts to identify potential treatments for patients with acute COVID-19, few therapies have demonstrated benefit, and these drugs appear to only be effective for certain subgroups of patients with COVID-19 [3, 4]. The recent approval of two vaccines offers promise for preventing new infections in the future [5, 6]. However, logistics of manufacturing and deploying the vaccine worldwide appear challenging, especially in resource-poor and developing nations [7–9]. Additionally, many people appear reluctant to receive SARS-CoV-2 vaccines even when they do become widely available [10]. Furthermore, vaccines are unlikely to completely eliminate COVID-19 in vaccinated populations [11–14]. Thus, COVID-19 may be a major cause of morbidity and mortality for the foreseeable future and effective therapies to treat patients moderately and severely ill with COVID-19 are urgently needed.

Rationale for convalescent plasma as a therapy for COVID-19
The use of convalescent plasma as a therapy for acute infections relies on the concept of transferring neutralizing antibodies from a person who recently recovered from the disease and developed a robust pathogen-specific immune response to another person who is in the early stages of the infection and has not fully developed his or her own immune response. This type of therapy is often called passive immune therapy or passive antibody therapy.

Based on strong biological rationale, convalescent plasma has been used for more than a century to treat outbreaks of viral diseases, especially when therapeutic options have been lacking [15, 16]. However, convalescent plasma therapy has rarely been evaluated by rigorously designed randomized trials, resulting in little empiric evidence to support its use. Argentine hemorrhagic fever is the only viral illness for which convalescent plasma was conclusively shown to be efficacious [17].

Expanded access program and emergency use authorization
Despite limited data on efficacy, hundreds of thousands of patients have received COVID-19 convalescent plasma outside of a clinical trial. The expanded access program (EAP) in the US for COVID-19 convalescent plasma was started in April 2020. More than 90,000 patients were treated in through this program, which was primarily designed to provide access to convalescent plasma early in the pandemic and only secondarily to evaluate safety and effectiveness [18, 19]. Less than 1% of treated patients experienced a transfusion reaction [20]. Because the program did not include a control group, efficacy was assessed by comparing clinical outcomes among patients who received convalescent plasma with high, medium, and low levels of SARS-CoV-2 antibodies, using the concept that better clinical outcomes in patients who received plasma with higher antibody levels would suggest efficacy [21]. Antibody levels were retrospectively measured with the Ortho-Clinical Diagnostics VITROS IgG semiquantitative assay and classified into the following three groups: (1) high antibody level (signal-to-cutoff ratio > 18.45); (2) medium antibody level (signal-to-cutoff ratio 4.62–18.45); and (3) low antibody level (signal-to-cutoff < 4.62). Among 3082 patients who received a single unit of convalescent plasma with measured antibody levels, and thus could be assigned to a single category of antibody level, 30-day mortality varied in a “dose-dependent” pattern by antibody titer level: 22.3% mortality in the high titer
group, 27.4% in the medium titer group, and 29.6% in the low titer group [19].

Citing results of the EAP, along with a small trial from China [22] and a trial from the Netherlands [23] that halted early, the Food and Drug Administration (FDA) issued an emergency use authorization (EUA) on August 23, 2020, for COVID-19 convalescent plasma to treat hospitalized COVID-19 patients [20]. At that time, the FDA concluded that existing evidence suggested that COVID-19 convalescent plasma with high antibody titer may be beneficial but emphasized that additional high-quality randomized clinical trials were important to more definitively understand the efficacy of COVID-19 convalescent plasma.

Clinical trials of COVID-19 convalescent plasma
COVID-19 convalescent plasma trials published after the announcement of the EUA include the PLACID [24] and PlasmAR [25] trials conducted among hospitalized adults in India and Argentina, respectively, and another trial of older outpatient adults in Argentina [26].

Neither PLACID nor PlasmAR suggested efficacy for COVID-19 convalescent plasma. PLACID enrolled 464 patients randomized to convalescent plasma administered in two 200 mL doses versus usual care in an unblinded fashion. Neutralizing capacity of the plasma was measured retrospectively and less than one-third of the units transfused in the study possessed neutralizing antibody titers \( \geq 1:80 \) by a microneutralization assay. The randomized, blinded, placebo-controlled PlasmAR trial enrolled 335 patients in a 2:1 convalescent plasma-to-placebo ratio. Convalescent plasma units were chosen for transfusion if they were found to have SARS-CoV-2 IgG titers 1:800 by the COVidar assay. Retrospective analysis of neutralizing titers in 125 (56%) of the infused doses showed an 80% inhibitory concentration median titer of 1:300. Treatment with convalescent plasma in this trial did not significantly improve clinical status at 30 days as measured on a six-level ordinal scale. A subsequent meta-analysis of available observational studies and clinical trials involving hospitalized patients suggested potential efficacy for COVID-19 convalescent plasma [27].

Libster et al. conducted a randomized trial of 160 outpatients who were \( \geq 65 \) years old with mild COVID-19 and symptoms < 72 h [26]. Participants were randomized in a 1:1 ratio to “high titer” COVID-19 convalescent plasma (IgG titer greater than 1:1000 against the spike protein) or placebo. Progression to severe respiratory disease, defined as a respiratory rate \( \geq 30 \) breaths/min or oxygen saturation < 93% while breathing room air, occurred in fewer patients randomized to convalescent plasma (16%) than placebo (31%), suggesting COVID-19 convalescent plasma treatment may be efficacious for early, mild disease [26].

Results from these trials published after the FDA emergency use authorization were unknown at the time that PassITON was designed. However, it is noteworthy that unlike PassITON, many prior studies of COVID-19 convalescent plasma either did not quantify SARS-CoV-2 antibody titers or screened convalescent plasma units for SARS-CoV-2 antibodies with binding assays without testing for neutralization. Among patients with high detectable levels of SARS-CoV-2 antibodies, only approximately 40–50% appear to have neutralizing function [28]. Therefore, many prior COVID-19 convalescent plasma studies likely included plasma units without neutralizing function.

Goal of this trial
Rigorous clinical trials evaluating the efficacy COVID-19 convalescent plasma with neutralizing activity are needed to guide clinical practice regarding the use of convalescent plasma during the current pandemic and also to understand if developing a scalable infrastructure for collecting, testing, and disseminating convalescent plasma is an important investment to prepare for future outbreaks of novel viruses. Convalescent plasma could be an immediately available therapy in the early stages of future viral pandemics in resource-rich and resource-limited nations. Understanding the efficacy of convalescent plasma in the current COVID-19 pandemic could help inform decisions on pursuing convalescent plasma as a therapy for future pandemics.

This study—the Passive Immunity Trial for Our Nation (PassITON)—was designed to provide the highest quality evidence on the efficacy of COVID-19 convalescent plasma as a therapy for adults hospitalized with moderate-to-severe acute COVID-19.

Methods
Design and oversight
PassITON is a multicenter, blinded, placebo-controlled, parallel group, randomized clinical trial evaluating the efficacy of COVID-19 convalescent plasma with neutralizing antibodies for the treatment of adults hospitalized with acute COVID-19. The trial is funded by the National Center for Advancing Translational Sciences (NCATS—https://ncats.nih.gov/contact) of the National Institutes of Health (NIH). NCATS played no part in study design, collection, management, analysis, or interpretation of data, writing of the report, or the decision to submit the report for publication. The trial is conducted at hospitals across the USA including both academic medical centers (many of which are part of the NCATS Clinical and Translational Science Awards (CTSA) Program) and regional/city hospitals. All US
hospitals with sufficient research enabling infrastructure are eligible to be a site in PassITON regardless of size or location.

Vanderbilt University Medical Center serves as the clinical coordinating center, data coordinating center, and single institutional review board (IRB number: 201672). The PassITON study team is located at Vanderbilt University Medical Center and is responsible for direct trial oversight via twice weekly meetings. This team is comprised of the study principal investigators, statisticians, project managers, operations managers, content experts, and study coordinators. Protocol-related changes, inclusion of ancillary studies, and other high-level decision-making are conducted by the PassITON Steering Committee (all site principal investigators) at biweekly meetings.

Treatment with convalescent plasma in this trial is through an investigational new drug (IND number 21080) application submitted to the FDA. The trial was registered with ClinicalTrials.gov (NCT04362176) prior to enrollment of the first participant on April 28, 2020. Progress and safety of the trial is monitored by an independent Data and Safety Monitoring Board (DSMB).

Prior to initiation of study procedures, informed consent is obtained by a trained study coordinator or investigator from each patient or a legally authorized surrogate decision-maker if the patient is unable to make medical decisions. On the consent form, participants are asked if they agree to use of their data should they choose to withdraw from the trial. Participants are also asked for permission for the research team to share relevant data with people from the sites taking part in the research or from regulatory authorities, where relevant. This trial does not involve collecting biological specimens for storage. Consent is obtained electronically or on paper. There is no anticipated harm from participating in this trial or provision for harm-related compensation.

The trial protocol was developed according to the SPIRIT guidelines (Supplementary Materials, Supplementary Figure 1). Protocol modifications and changes to study-related procedures are communicated to the study team and investigators through twice weekly internal coordinating center team meetings, weekly PassITON newsletters disseminated both internally and externally to site staff and investigators, and biweekly Steering Committee meetings attended by site investigators and coordinators.

**Collection of convalescent plasma**

The plasma collection component of PassITON was developed to optimize the efficient procurement of COVID-19 convalescent plasma with high levels of neutralizing antibodies. Convalescent plasma is collected from adults mainly residing around Nashville, Tennessee who have recovered from COVID-19 in a collaborative effort between Vanderbilt University Medical Center and Blood Assurance, a nonprofit regional blood center based in Chattanooga, Tennessee. Patients with laboratory-confirmed SARS-CoV-2 infection with self-reported symptom severity of at least 3 on a 10-point scale (range: 1, “I feel healthy” to 10, “I was/should have been in the Intensive Care Unit (ICU)”) are eligible for plasma donation. Recovered patients are identified through several methods including Vanderbilt hospital records, mass email through the Vanderbilt employee list, public advertising in the community, ResearchMatch [29, 30], and self-identification. Patients are able to donate plasma if they have recovered from acute COVID-19, defined as either: (1) being symptom-free for 14 days and having at least one negative COVID-19 test by RT-PCR, or (2) being symptom-free for at least 28 days. All donors must also meet FDA requirements for blood product donation [31]. Donors sign an IRB-approved informed consent for participation prior to phlebotomy. Donors have a blood sample collected for characterization of circulating SARS-CoV-2 antibodies (see next section) and then immediately have blood collected for plasma donation units (Fig. 1).

Plasma collection is performed via apheresis using the Fresenius-Kabi ALYX instrument, which allows for the collection of up to four units per donation. Patients are invited to return for additional donations if antibody testing demonstrates high antibody levels (≥ 20,000 EU/mL by anti-Receptor Binding Domain (RBD) IgG binding assay) and neutralizing activity. Through an FDA variance obtained by Blood Assurance, participants are allowed to donate as frequently as every 7 days for 4 visits before evaluation of total protein and serum albumin to confirm safety of continued donations.

**Selection of convalescent plasma for the trial**

Serum is obtained from convalescent plasma donors at the time of donation. These serum samples are used for antibody quantification. Donor sera are initially screened by the Abbott™ ARCHITECT™ IgG qualitative platform for the presence of detectable antibody against SARS-CoV-2. Samples positive in the Abbott assay are then assessed by the quantification of binding IgG against the RBD of SARS-CoV-2 using a liquid bead-array assay as previously described [32]. Briefly, recombinant RBD is conjugated to Luminex MagPlex microspheres and incubated in 96 well plates with serially diluted serum samples and a cross- reactive SARS-CoV-2 monoclonal antibody as a standard. Serum antibodies bound to SARS-CoV-2 S RBD are detected by R-Phycerythrin conjugated F(ab)2 fragment goat anti-human IgG Fc gamma conjugate (Jackson ImmunoResearch). Data are
acquired using a Luminex MagPix Instrument at 100 beads per well, with Xponent software version 4.3.

Through September 30, 2020, donor samples were screened exclusively using the Abbott™ ARCHITECT™ platform and the RBD Luminex assay (Fig. 2). Units with a minimum threshold mean fluorescence intensity (MFI) of 8000 were deemed eligible for transfusion. This cutoff was determined by screening a subset of samples for neutralization using a traditional live-virus plaque-reduction neutralization titer (PRNT) assay. Two- or four-fold serial dilutions of sera in gelatin saline were incubated for 20 min at 37 °C with an average of 130 plaque-forming units of SARS-CoV-2 isolate SARS-CoV-2/human/USA/USA-WA1/2020 (GenBank: MN985325.1) in 200 μl gelatin saline, and 100 μl of virus-serum mixtures were applied to each of two Vero E6 cell monolayers in 10 cm² dishes. Following virus adsorption for 30 min at 37 °C, monolayers were overlaid with 1% agar in cell culture medium and incubated for 3 days at 37 °C, at which time plaques were enumerated by direct visual inspection. Percent neutralization was defined as fractional plaque reduction in the presence of serum relative to untreated (saline only) virus. Neutralization titers were interpolated from dose-response curves fit to results of duplicate neutralization testing using five-parameter logistic regression modeling implemented in GraphPad Prism.

Beginning October 1, 2020, an additional screening step was introduced to confirm the presence of SARS-CoV-2 neutralizing antibodies. In the modified format, donor samples still undergo screening via the Abbott™ ARCHITECT™ platform and the RBD Luminex assay. Samples are excluded if they are found to be negative via the Abbott™ ARCHITECT™ of having an MFI < 8000 as determined by the RBD Luminex assay. Samples with an antibody level (MFI) above 8000 are then screened for the ability to neutralize virus by functional assessment with a high-throughput assay platform using real-time, quantitative cellular analysis on the xCELLigence platform (Agilent Technologies, Santa Clara, CA), using chimeric vesicular stomatitis virus (VSV) expressing intact SARS-CoV-2 spike protein, as previously described [33, 34]. Samples with a 50% neutralization titer > 1:50 are selected for transfusion in the trial (Fig. 2).

Antibody testing is completed at Vanderbilt University Medical Center. Convalescent plasma units are stored at Blood Assurance and shipped to enrolling sites in the trial as needed. Between April 22, 2020, and January 29, 2021, 429 donors provided over 1200 convalescent plasma units, with plans to continue donations for the duration of the trial. Approximately 25% of the plasma donations in this program have passed the antibody screening steps and been selected for use in the trial.

**Trial participants**

Patients eligible for enrollment in the trial include adults hospitalized with laboratory-confirmed SARS-CoV-2 infection and respiratory symptoms consistent with COVID-19 for fewer than 14 days. Patients hospitalized in either ICU or less intensive areas are eligible. Major exclusion criteria include planned hospital discharge.
within 24 h and prior receipt of COVID-19 convalescent plasma or another passive immunity therapy in the prior 30 days. Participants identified as eligible for the study are approached for consent by a study coordinator or investigator. Recruitment materials include a flyer, fact sheet, and website (https://passitonstudy.org) which contains informative videos from physicians, researchers, and past participants. All recruitment materials have been translated to Spanish, Arabic, and simple Chinese. To further support recruitment, there are fully translated consent forms in > 20 languages. PassITON recruitment will continue at all sites until the accrual goal of 1000 participants is met.

Randomization and treatment groups
Enrolled patients are randomized in a 1:1 ratio to COVID-19 convalescent plasma or placebo. Randomization is completed by a centralized web-based platform and stratified by site, sex, and age. Patients randomized to convalescent plasma receive a single dose of 1 unit (200–399 mL) of COVID-19 convalescent plasma infused intravenously. Patients randomized to placebo receive a single 250 mL dose of lactated Ringer’s solution containing multivitamin infused intravenously. Multivitamins are added to the placebo solution to produce a yellow color that matches the color of plasma.

The study infusion (convalescent plasma or placebo) is administered as soon as possible and within 24 h after randomization. Infusion of study treatment is halted if the study participant exhibits any symptoms of transfusion reaction or anaphylaxis. Patients are observed for 6 h after initiation of the study infusion for signs and symptoms of a transfusion reaction. Use of open-label convalescent plasma is strongly discouraged for the first 14 days following the study infusion. Other aspects of clinical management are performed at the discretion of the treating clinicians without influence from the study protocol.

Blinding
In order to safely administer a blood product in the trial and also maintain blinding of the patient, investigators, and outcome assessors, the trial uses both blinded and unblinded study personnel. At each site, the lead investigator remains blinded to study group assignment. An unblinded study member randomizes patients, receives the treatment assignment, and then orders convalescent plasma or the placebo solution based on the randomized treatment assignment. The study treatment is delivered to the patient’s bedside, where an unblinded clinical nurse places the study treatment in a blinding bag before entering the patient’s room. The unblinded clinical nurse then infuses the treatment. Clinical monitoring, including vital sign assessment, is completed based on local practices for monitoring an infusion of plasma regardless of randomized group. The clinical providers (e.g., physicians), patient, and outcome assessors remain blinded to study group assignment. Participant unblinding is performed by unblinded site coordinators and is permitted only after the study follow-up period is complete and if unblinding will directly impact the individual’s course of clinical care (e.g., timing of COVID-19 vaccination).

Outcomes
The primary outcome is the patient’s clinical status on a 7-category ordinal scale (the COVID-19 7-point Ordinal Clinical Progression Outcomes Scale) 14 days after the study infusion. The 7 categories are (1) not hospitalized with resumption of normal activities; (2) not hospitalized, but unable to resume normal activities; (3) hospitalized, not on supplemental oxygen; (4) hospitalized, and on supplemental oxygen; (5) hospitalized, on nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both; (6) hospitalized, on ECMO, invasive mechanical ventilation, or both; and (7) death. While the patient is hospitalized, the ordinal scale category is identified by direct patient observation and medical record review. After hospital discharge, patients are contacted by telephone to distinguish between category 1 and category 2. This scale was developed by the World Health Organization [35] (WHO) early in the pandemic as a patient-centered clinical outcome for COVID-19 and has been successfully used in multiple clinical trials [3, 36, 37]. Secondary and safety outcomes are shown in Table 1.

Data collection, monitoring, and dissemination
Randomization and data collection are being conducted through Research Electronic Data Capture (REDCap). The randomization module in REDCap allows the statistician to load a randomization table that will allow the study personnel to click a “randomize” button. REDCap is a secure, web-based application designed to support data capture for research studies, providing (1) an intuitive interface for validated data entry; (2) audit trails for tracking data manipulation and export procedures; (3) automated export procedures for seamless data downloads to common statistical packages; and (4) procedures for importing data from external sources.

Data quality is reviewed remotely using front-end range and logic checks at the time of data entry and back-end monitoring of data using application programming interface tools connecting the online database to statistical software to generate data reports. Patient records and case report forms are also be reviewed to evaluate the accuracy and completeness of the data entered into the database and monitored for protocol compliance per the study monitoring plan.
The data generated from the PassITON trial will be released via publication. It will also be shared at seminars, symposiums, and meeting presentations as well as deposited in appropriate databases. Before releasing any of this information, the raw data will be stripped of identifiers in order to remain compliant with HIPAA and other governing agencies’ guidelines. The datasets analyzed during the current study are available from the corresponding author upon reasonable request.

### Statistical analysis

In this section, we describe key statistical features of the trial. The full statistical analysis plan for the trial is included in the Supplementary Materials.

#### General approach to analysis

The statistical design for this trial was informed by the need to learn as rapidly as possible from the data during the pandemic while simultaneously managing the risk of drawing erroneous conclusions. Rapid decision-making to maximally inform clinical care during an ongoing pandemic requires flexibility for the DSMB to perform unplanned evaluations of the data and potentially decrease or increase the sample size of the trial. This requires a trial framework that does not demand that all possible interim analyses are prespecified, as is required of approaches using \( p \) values. Two closely related approaches which offer the needed flexibility are the Likelihood and Bayesian frameworks. We selected the Likelihood framework for this trial. The Likelihood approach has been successfully implemented in clinical trials with continuous monitoring or sequential methods \([38, 39]\), because it retains its meaning and reliability regardless of the number of interim analyses or outcomes under consideration \([40, 41]\).

Decision-making using the likelihood approach in a clinical trial centers on three quantities: the point estimate of the treatment effect (an odds ratio, for example), a corresponding interval estimate, and a single number summary that measures the relative evidence for one hypothesis (for example, convalescent plasma being superior to placebo) compared to another hypothesis (for example, convalescent plasma not being superior to placebo). These three quantities are similar to the point estimate, 95% confidence interval, and \( p \) value that are generated in frequentist analyses. In fact, point estimates

| Outcomes | Variable type | Approach to analysis |
|----------|--------------|----------------------|
| **Efficacy outcomes** | | |
| COVID-19 7-point Ordinal Clinical Progression Outcomes Scale 14 days after randomization (assessed on study day 15) | Ordinal | Cumulative probability model with logit link |
| All-location, all-cause 14-day mortality (assessed on study day 15) | Binary | Logistic regression |
| All-location, all-cause 28-day mortality (assessed on study day 29) | Binary | Logistic regression |
| Survival through 28 days | Time-to-event | Proportional hazards regression |
| Time to hospital discharge through 28 days | Time-to-event | Multistate model with death as a competing risk |
| Time to recovery | Time-to-event | Cumulative probability model with logit link |
| COVID-19 7-point Ordinal Clinical Progression Outcomes Scale on study days 3, 8 and 29 | Ordinal | Cumulative probability model with logit link |
| Oxygen-free days through day 28 | Ordinal | Cumulative probability model with logit link |
| Ventilator-free days through day 28 | Ordinal | Cumulative probability model with logit link |
| Vasopressor-free days through day 28 | Ordinal | Cumulative probability model with logit link |
| ICU-free days through day 28 | Ordinal | Cumulative probability model with logit link |
| Hospital-free days through day 28 | Ordinal | Cumulative probability model with logit link |
| **Safety outcomes** | | |
| Receipt of renal replacement therapy | Binary | Risk difference |
| Venous thromboembolic disease (deep vein thrombosis or pulmonary embolism) | Binary | Risk difference |
| Cardiovascular event (myocardial infarction or ischemic stroke) | Binary | Risk difference |
| Transfusion reaction | Binary | Risk difference |
| Transfusion related acute lung injury (TRALI) | Binary | Risk difference |
| Transfusion associated circulatory overload (TACO) | Binary | Risk difference |
| Transfusion-related infection | Binary | Risk difference |
using the likelihood and frequentist approaches are often identical, and the interval estimates are often very similar to 95% confidence intervals. The likelihood ratio (LR) and the *p*-value, however, are distinct measures of evidence. The LR is a ratio: the density of the trial data if the treatment is effective (alternative hypothesis) divided by the density of the trial data if the treatment is not effective (null hypothesis). A LR of 1 indicates the data are neutral; neither the alternative hypothesis nor null hypothesis is supported more strongly than the other. A large LR is evidence in support of the treatment being effective. An LR less than one is evidence that the treatment is harmful. In this trial, a LR ≥ 7 in favor of the intervention group is considered sufficient evidence to assert that the treatment is beneficial.

The likelihood approach is different than using *p*-values as the level of evidence because the *p*-value compares what actually happened in the trial to what might have happened if the trial were repeated infinitely and the null hypothesis was true. Because it is impossible to compute what might have happened if the rules for decision-making are not fully predefined, using a *p*-value for decision making is not well suited for a trial like this in which pandemic circumstances prompt urgent design changes. The LR approach, on the other hand, is based on a relative likelihood of observed outcomes under two competing models at the same point in time, making it especially appropriate for settings where pre-specification of the timing or frequency of sequential analyses is not possible.

**Interim analyses**

The anticipated sample size is 1000 enrolled patients. The trial includes three planned interim analyses, to be conducted after primary outcome data collection is completed for 150, 450, and 750 study participants. Additional interim analyses may be called at any time by the DSMB based on changes in the pandemic and/or emerging data on COVID-19 convalescent plasma. Adverse events, safety outcomes, protocol deviations, and the primary endpoint are presented to the DSMB at each interim analysis. Additionally, as a safety evaluation, the difference in mortality risk between groups is calculated, and the one-sided hypothesis that mortality risk in the intervention arm exceeds the mortality risk in placebo will be compared to the null hypothesis of equal mortality risk. The trial will be stopped for safety if the likelihood ratio for mortality exceeds any of the following thresholds, suggesting increased mortality with convalescent plasma: first interim analysis, LR 6.3 (which corresponds to a *p*-value of approximately 0.0275); second interim analysis, LR 4.0 (which corresponds to a *p*-value of approximately 0.0479); and third interim analysis, LR 3.3 (which corresponds to a *p*-value of approximately 0.0612). These thresholds result in a 0.1 trial-wise risk of stopping the trial early for mortality if mortality were truly equivalent in the intervention and control groups. There are no pre-specified stopping rules for efficacy.

**Primary analysis of the primary outcome**

The primary analysis will be intention-to-treat, with each randomized patient analyzed according to the randomized treatment assignment (convalescent plasma vs. placebo) regardless of the treatment received. The main result will be an estimate of the treatment effect odds ratio, its likelihood ratio when compared to the null, and the corresponding 1/7 likelihood support interval, all of which will be estimated from a cumulative probability ordinal regression model (CPM) with logit link. The marginal likelihood function for the treatment effect parameter will be the asymptotic regression coefficient distribution; specifically, it will be the normal distribution density function with mean and standard deviation equal to the regression estimates. An odds ratio < 1.0 indicates more favorable results on the COVID 7-point Ordinal Clinical Progression Outcomes Scale in the intervention group compared with the control group. Likelihood ratios more extreme than 7 will be interpreted as sufficient evidence to assert efficacy.

The primary model will adjust for the following six baseline characteristics: age (2 parameters, restricted cubic spline); sex (1 parameter); baseline SOFA score (1 parameter, linear term); baseline COVID-19 7-point Ordinal Clinical Progression Outcomes Scale score (possible range: 3–6) (2 parameters, quadratic); time from symptom onset to randomization in days (2 parameter, non-linear term); and a site indicator variable (as a random effect).

**Additional analyses of the primary outcome**

A per-protocol analysis of the primary outcome will be performed in which randomized patients who did not receive any volume of the study treatment are excluded.

The impact of convalescent plasma quality, as measured by antibody quantification and neutralization, on the primary outcome will be estimated with two ordinal regression models. In the first, the model will include the same covariates listed for the primary analysis with the addition of a measure of donor plasma binding level (value in MFI obtained using the RBD Luminex-based assay [32]). In the second model, a measure of donor plasma neutralization (NT50 value obtained using the VSV-SARS-CoV-2 chimeric virus neutralization assay [33, 34]) will be used. Both of these variables of convalescent plasma quality will be included in the models as a restricted cubic spline with three knots to capture potential non-linear associations with the outcome. For observations in the control arm, binding and neutralization
values will be set to zero. Studies to evaluate alternative measures of convalescent plasma quality are ongoing and, dependent on the results of those analyses, a different measure of quality may be selected.

The degree to which pre-specified baseline variables modify the treatment effect will be examined with tests of statistical interaction in a cumulative probability ordinal regression model. Independent variables will include study group assignment, the potential effect modifier of interest, the interaction between the two, and the same pre-specified covariates used in the primary model. Presence of effect modification will be assessed by reference to the LR for the interaction term, with values greater than 6 considered to suggest a potential interaction and values greater than 7 considered to confirm an interaction. The baseline variables that will be evaluated for effect modification include: baseline recipient (trial participant) serum antibody quantification; baseline COVID-19 7-point Ordinal Clinical Progression Outcomes Scale score; baseline SOFA score; location at time of enrollment (ICU/ward); age; race/ethnicity; duration of COVID-19 symptoms prior to randomization (days in linear form); and mechanical ventilation status at baseline.

Sample size and power

The operating characteristics of the trial design were estimated by simulating study data to reflect different treatment effect sizes. Simulations for study power were performed on Amazon Elastic Compute Cloud servers using R version 4.0.2 [42] with the following packages: ordinal [43], magrittr [44], and doRedis [45]. The simulated study dataset was evaluated according to the stopping rule and analysis plan described above. For each effect size, 1000 simulated datasets were analyzed. A type I error occurred if the study asserted efficacy when in fact there was no treatment effect. The type I error rate was calculated as the proportion of simulated studies with no treatment effect in which the error occurred. A type II error occurred if the study failed to assert efficacy when there was a beneficial treatment effect. For each treatment effect, power was calculated as the proportion of simulated studies that did not result in a type II error.

The study endpoint for control subjects was simulated to match the outcomes in the control arm of a recent clinical trial [46]. In each simulation setting, the distribution for the treatment arm was calculated by adjusting the control arm outcome distribution according to the setting-specific treatment effect size and data generation model.

These simulations demonstrated that enrollment of 1000 patients (500 patients in the intervention group and 500 patients in the control group) would provide 80% power to detect an adjusted odds ratio of $\leq 0.73$ (Fig. 3). Some trials orient the ordinal outcomes scale in the reverse direction, with an odds ratio greater than 1.0 indicating benefit from the intervention [3, 36]. With reversal of the ordinal outcomes scale, enrollment of 1000 patients would provide 80% power to detect an adjusted odds ratio $\geq 1.37$. The simulations also demonstrated that the type I error rate was below 0.05.

Analysis of secondary and safety outcomes

Secondary efficacy outcomes will be assessed by intention-to-treat analyses using the same covariates as the primary model for the primary outcome. Safety outcomes will be analyzed in the safety population, classified based on receipt of convalescent plasma from the trial vs. those who received placebo from the trial regardless of randomized assignment, without covariate adjustment. Adjustments will not be made for multiple comparisons.

Discussion

PassITON is an ongoing blinded, placebo-controlled randomized trial evaluating the efficacy of COVID-19 convalescent plasma for the treatment of adults hospitalized with moderate-to-severe acute COVID-19. The first patient was enrolled on April 28, 2020, and trial completion is anticipated in 2021.

COVID-19 convalescent plasma has been administered to hundreds of thousands of patients in the USA, initially under an EAP [47] and now under EUA [20]. While data from these programs support the safety of
convalescent plasma, evidence of efficacy is lacking. PassITON is designed to provide rigorous efficacy data. As such, key design features include meticulous selection of convalescent plasma with high levels of anti-SARS-CoV-2 antibodies with neutralizing activity; enrollment of a geographically diverse patient population in hospitals across the USA; patient-level randomization to COVID-19 convalescent plasma or matching placebo; blinding of participants, investigators and outcome assessors to treatment assignment; and systematic collection of patient-centered outcomes for 4 weeks following infusion of the study treatment. These characteristics distinguish PassITON from many other COVID-19 convalescent plasma trials which have either reported null findings (PLACID 24, PlasmAR 25) or recently stopped for futility [48, 49].

In addition, the rigorous plasma donation and screening program required in PassITON to ensure the use of COVID-19 convalescent plasma with potent neutralizing antibodies has demonstrated important challenges that would need to be overcome to develop a scalable pipeline for supplying neutralizing COVID-19 convalescent plasma if it is found to be an effective therapy. With only approximately 25% of units donated from patients who have recovered from COVID-19 having neutralizing activity, stringent donor screening and antibody quantification steps would need to be implemented to ensure the use of effective convalescent plasma.

PassITON evaluates the efficacy of COVID-19 convalescent plasma among hospitalized patients, which is the same population described in the FDA EUA 20. The efficacy of COVID-19 convalescent plasma among patients with less severe disease and/or who are earlier in their disease course is being evaluated in other trials [50, 51].

Convalescent plasma had been used as a therapy for severe viral illnesses for over a century and in hundreds of thousands of COVID-19 patients during the past year. Despite this enthusiastic use of convalescent plasma, its clinical efficacy remains unclear. Effectively managing COVID-19 patients in the current pandemic and developing a robust infrastructure to respond to future viral pandemics requires evidence-based answers to longstanding questions about the efficacy of convalescent plasma. PassITON will advance our understanding of convalescent plasma, and combined with other work, help inform treatment options for COVID-19 and future pandemics.

**Trial status**

The PassITON trial launched in April 2020 as a single-center study at Vanderbilt University Medical Center with funding from the Dolly Parton COVID-19 Research Fund. The trial expanded to a multicenter study in August 2020 with funding from the NCATS of the National Institutes of Health (NIH). Prior to expansion to the multicenter format, 66 participants had been enrolled at Vanderbilt. Interim analyses conducted by the independent DSMB after enrollment and completion of the primary outcome by 151 and 469 study participants resulted in recommendations to continue the study without modification. PassITON is currently enrolling under protocol version 5.0 dated September 15, 2020. Trial completion is expected by May 31, 2021.

**Abbreviations**

SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; COVID-19: Coronavirus disease 19; CTSA: Clinical and Translational Science Award; DSMB: Data Safety Monitoring Board; EAP: Expanded access program; ELISA: Enzyme-linked immunosorbent assay; FDA: Food and Drug Administration; ICU: Intensive care unit; IND: Investigational new drug; IRB: Institutional Review Board; LR: Likelihood ratio; NCATS: National Center for Advancing Translational Science; NIH: National Institutes of Health; PassITON: Passive Immunity Trial for Our Nation; PRNT: Plaque Reduction Neutralization Titer; RBD: Receptor Binding Domain; VSV: Vesicular somatitis virus

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s13063-021-05171-2.

**Acknowledgements**

Not applicable

**Disclaimer**

The content of this manuscript is the responsibility of the authors alone and does not necessarily reflect the views or policies of the National Institutes of Health or the National Center for Advancing Translational Sciences.

**Authors’ contributions**

All authors read and approved the final manuscript. Study concept and design: Self, Stewart, Wheeler, Casey, Chappell, Lindsell, Pulley, Rhoads, Thorsen, Bernard, Rice. Drafting of the manuscript: Self, Stewart, Wheeler, Chappell, Lindsell, Rhoads, Bernard, Rice. Critical revision of the manuscript: All authors. Obtained funding: Pulley, Bernard. Study supervision: All authors.

**Authors’ information**

Not applicable

**Funding**

Primary funding for this work was provided by the NCATS award 3UL1TR002243-04S3. Funding for REDCap, trial innovation work, and the other tools was provided by NCATS award No. UL1TR002243. Funding for pilot work was provided by the Dolly Parton COVID-19 Research Fund.

**Availability of data and materials**

Not applicable.

**Declarations**

**Ethics approval and consent to participate**

Ethics approval was granted by the Vanderbilt University Institutional Review Board (IRB) for a single site study on April 23, 2020 (IRB#200738). The Vanderbilt University IRB currently acts as the single IRB for the multi-center PassITON study. Approval for this study was received on September 21, 2020. Informed consent is obtained from all participants or their legally authorized representatives prior to involvement in the study.
Consent for publication
Not applicable.

Competing interests
All authors submitted a competing interest form at the time of manuscript submission. The authors declare that they have no competing interests.

Author details
1Vanderbilt Institute for Clinical and Translational Research (VCTR), Vanderbilt University Medical Center, Nashville, TN 37232, USA. Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, USA. 2Department of Biostatistics, Vanderbilt University Medical Center, Nashville, USA. 3Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, USA. 4Division of Infectious Diseases, Department of Internal Medicine, The University of Kansas School of Medicine, Kasas, USA. 5Division of Medicine, Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, USA. 6Division of Hematology and Oncology, Louisiana State University Health-Sciences Center, New Orleans, USA. 7Division of Infectious Diseases, Department of Pediatics, Vanderbilt University Medical Center, Nashville, USA. 8Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, USA. 9Division of Pulmonary Disease and Critical Care Medicine, Department of Internal Medicine, Virginia Commonwealth University, Richmond, USA. 10Department of Critical Care, Respiratory Institute, Cleveland Clinic Healthcare System, Cleveland, USA. 11Division of Transfusion Services, Department of Pathology, University of Maryland School of Medicine, Baltimore, USA. 12Department of Emergency Medicine, University of Colorado School of Medicine, Boulder, USA. 13Department of Medicine, University of New Mexico School of Medicine, Albuquerque, USA. 14Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Utah, Salt Lake City, USA. 15Intermountain Healthcare, Salt Lake City, USA. 16Division of Pathology and Laboratory Medicine, University of Arkansas for Medical Sciences, Fayetteville, USA. 17Division of Hospital Medicine, Scripps Clinic, Scripps Research Translational Institute, The Scripps Research Institute, San Diego, USA. 18Department of Emergency and Division of Pulmonary, Critical Care Medicine, and Sleep Medicine, University of Washington, Seattle, USA. 19Department of Emergency Medicine, University of Mississippi Medical Center, Oxford, USA. 20Department of Internal Medicine, Division of Infectious Disease, Rochester General Hospital, Rochester, USA. 21Department of Pharmacy, Newton-Wellesley Hospital, Massachusetts College of Pharmacy and Health Sciences, Boston, USA. 22Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, State University of New York at Buffalo, Buffalo, USA. 23Department of Pathology, University of Utah, Salt Lake City, USA. 24Division of Pulmonary and Critical Care, Louisiana State University Health-Sciences Center, New Orleans, USA. 25Division of Pulmonary, Critical Care, and Sleep Medicine, The Ohio State University, Columbus, USA. 26Sentara Pulmonary, Critical Care, and Sleep Specialists, Sentara Health, Eastern Virginia Medical School, Norfolk, USA. 27Department of Pathology, University of New Mexico School of Medicine, Albuquerque, USA. 28Sentara Pulmonary, Critical Care, and Sleep Medicine, University of Virginia, Charlottesville, VA. 29Department of Medicine, University of Chicago, Chicago, USA.

Received: 9 February 2021 Accepted: 5 March 2021 Published online: 20 March 2021

References
1. del Rio C, Malani PN. COVID-19—new insights on a rapidly changing epidemic. JAMA. 2020;323(14):1339–40. https://doi.org/10.1001/jama.202 0.3072.
2. WHO Coronavirus Disease (COVID-19) Dashboard. n.d. https://covid19.who. int. Accessed 17 Dec 2020.
3. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetskemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Derberger K, Tapsow V, Hishel L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC, ACTT-1 Study Group Members. Remdesivir for the treatment of Covid-19 — final report. N Engl J Med. 2020;383(19):1813– 26. https://doi.org/10.1056/NEJMoa2007784.
4. The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;393(4):859–70. https://doi.org/1 0.1056/NEJMoa201436.
5. Pfizer–BioNTech COVID-19 Vaccine. FDA. 2020. https://www.fda.gov/ emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine. Accessed 17 Dec 2020.
6. Moderna COVID-19 Vaccine. FDA. 2020. https://www.fda.gov/emergency- preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccine. Accessed 11 Jan 2021.
7. Sharma O, Sultan AA, Ding H, Triggle CR. A review of the progress and challenges of developing a vaccine for COVID-19. Front Immunol. 2020;11: 585354. https://doi.org/10.3389/fimmu.2020.585354.
8. Mills MC, Salisbury D. The challenges of distributing COVID-19 vaccinations. eClinicalMedicine. 2020;100674. https://doi.org/10.1016/j.eclinm.2020.100674.
9. The Lancet Microbe. COVID-19 vaccines: the pandemic will not end overnight. Lancet Microbe. 2021;2(1):e1. https://doi.org/10.1016/S2666-524 7(20)30226-3.
10. Lazarus JV, Ratzan SC, Palayew A, Gostin LO, Larson JH, Rabin K, Kimball S, el-Mohandes A. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med. 2020;26–4. https://doi.org/10.1038/s41591-020-1124-9.
11. Pollack FP, Thomas SJ, Kitchin N, Absalon J, Gutman A, Lockhart S, Perez JL, Perna FC, Marc G, Moreira ED, Zerbin C, Bailey R, Swanson KA, Roychoudhury S, Kouy K, Li P, Kalina WV, Cooper D, French RW Jr, Hammitt LL, Tureci O, Nell H, Schaefer A, Ural S, Trevisan DB, Mather S, Dormitzer PR, Sahin U, Jansen KJ, Gruber WC, C591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15. https://doi.org/10.1056/NEJMoa2034577.
12. Baden LR, El Sahly HM, Essink B, Katloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2020. NEJMoa2035389. https://doi.org/10.1056/NEJMoa2035389.
13. Kupferschmidt K. New mutations raise specter of ‘immune escape’. Science. 2021;371(6527):329–30. https://doi.org/10.1126/science.371.6527.329.
14. Andreano E, Piccini G, Licastro D, Casalino L, Johnson NV, Paciello I, et al. SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma. Immunology. 2020. https://doi.org/10.1101/2020.12.2 6.424451.
15. Casadevall A. Passive antibody therapies: progress and continuing challenges. Clin Immunol. 1999;93(1–5):15–5. https://doi.org/10.1006/clic. 1999.4768.
16. Casadevall A, Dadachova E, Plohfki L. Passive antibody therapy for infectious diseases. Nat Rev Microbiol. 2004;2(9):695–703. https://doi.org/10.1038/ nrmmicro9794.
17. Maztegui JF, Fernandez NJ, De Damiando AJ. Efficacy of immune plasma in treatment of argentine hemorrhagic fever and association between treatment and a late neurological syndrome. Lancet. 1979;1(4154):1216–7. https://doi.org/10.1016/S0140-6736(79)92335-3.
18. Joyner MJ, Wright RS, Fainweather D, Seneffel JW, Bruno KA, Klassen SA, Carter RE, Klopma AM, Wiggins CC, Shepherd JRA, Ray RF, Whelan ER, Clayburn AJ, Spiegel MR, Johnson PW, Lesser ER, Baker SE, Larson KF, Ripoll JS, Andersen KJ, Hodge DO, Kunze KL, Buras MR, Vogt MNP, Herasevich V, Dennis JG, Regimbial RJ, Bauer PR, Blair JE, van Buskirk CM, Winters JL, Stubbs JR, Paneth NS, Verdun NC, Marks P, Casadevall A. Early safety indicators of COVID-19 convalescent plasma in 5000 patients. J Clin Investig. 2020;130(9): 4791–7. https://doi.org/10.1172/JCI114202.
19. Joyner MJ, Carter RE, Seneffel JW, Klassen JA, Mills JR, Johnson PW, et al. Convalescent plasma antibody levels and the risk of death from Covid-19. N Engl J Med. 2021;395:1818–33. https://doi.org/10.1056/NEJMoa2101893.
20. U.S. Food and Drug Administration. COVID-19 Convalescent Plasma EUSA Decision Memo 2020. https://www.fda.gov/media/141480/download. Accessed 9 Dec 2020.
21. Joyner MJ, Seneffel JW, Klassen SA, Mills JR, Johnson PW, Theel ES, et al. Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience. In: Infectious Diseases (except HIV/AIDS). 2020. https://doi.org/10.10117/CLID1142020.
22. Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, Kong Y, Ren L, Wei Q, Mei H, Hu C, Tao C, Yang R, Wang J, Yu Y, Guo Y, Wu X, Xu Z, Zeng L, Xiong N, Chen L, Wang J, Man N, Liu Y, Xu H, Deng E, Zhang X, Li C, Wang C, Su S,
Zhang L, Wang J, Wu Y, Liu Z. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA. 2020;324(5):460–70. https://doi.org/10.1001/jama.2020.10044.

23. Gharibharan A, Jordans CCE, GeurtsvanKessel C, den Hollandier JG, Karim F, Mollema PPN, et al. Convalescent plasma for COVID-19: A randomized clinical trial. MedRes. 2020;2020(07):01.20193857. https://doi.org/10.1101/2020.07.01.20193857.

24. Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID trial). BMJ. 2020;371:m3939. https://doi.org/10.1136/bmj.m3939.

25. Simonovitch VA, Burgos Pratx LD, Scibona P, Beruto MV, Vallone MG, Vázquez C, Savoy N, Giunta DH, Pérez LG, Sánchez MDL, Gamamik AV, Ojeda DS, Santoro DM, Camino PJ, Antelo S, Rainero K, Vidalia GP, Miyazaki EA, Cornstein W, Trabado EA, Ross FM, Spotti M, Funtowicz G, Scordo WE, Losso MH, Ferniott J, Pardo PE, Rodriguez E, Rucci P, Pasquali J, Fuentes NA, Esperatti M, Speroni GA, Nannini EC, Matteuccio A, Michelangeli HG, Follmann D, Lane HC, Bellosio WH, Plasma Study Group. A randomized trial of convalescent plasma in COVID-19 severe pneumonia. N Engl J Med. 2020;384(7):619–29. https://doi.org/10.1056/NEJMoa2031304.

26. Libster R, Pérez Marc G, Wappner D, Coviello S, Bianchi A, Braem V, et al. Self et al. Trials. 2021;22:221.

27. Case JB, Rothlauf PW, Chen RE, Liu Z, Zhao H, Kim AS, Bloyet LM, Zeng Q, Eldridge A, Lord C, Shapiro N, Talmor D, O’Flaherty N, Brait K, Jones A, Galbraith J, Peacock R, Nandi U, Wachs T, Matthay M, Liu S, Schermerhorn M, Banner-Goodspeed V, Boyle K, Dubosh N, Filbin M, Hibbert K, Parny B, Lavrin-Parisons K, Pulido N, Lilley B, Lodesten C, Margolin J, Bratt K, Jones A, Galbraith J, Peacock R, Nandi U, Wachs T, Matthay M, Liu K, Kangelaris K, Wang R, Caffee C, Yee K, Hendey G, Chang S, Lim G, Qadir N, Tam A, Beutler R, Levitt J, Wilson J, Rogers A, Vojnik R, Roque J, Albertson T, Chenoweth J, Adams J, Pearson S, Juarez M, Almasri E, Fayed M, Hughes A, Hillard S, Huebinger R, Wang H, Vidales E, Patel B, Ginde A, Mosi M, Badashavili A, Mckeenan J, Finck L, Higgins C, Howell M, Douglass I, Haukoos JS, Higley T, Lytle C, Cupelo A, Caruso E, Camacho C, Gravitz S, Finigan J, Griesmer C, Park P, Hyzy R, Nelson K, McDonough K, Olbrich N, Williams M, Kapoor R, Nash J, Willing M, Ford H, Gardner-Gray J, Ramesh M, Moses M, Ng Gong M, Abodoo M, Aisghar A, Amosu O, Torres M, Kaur S, Chen JT, Hope A, Lopez B, Rosales K, You Young J, Mosier J, Hypes C, Natt B, Borg B, Salvagio Campbell E, Hite RD, Huddock K, Cresie A, Allihan F, Gomez-Arroyo J, Duggal A, Mehkri O, Hastings A, Sahoo D, Abi Fadel F, Cole S, Shaner V, Winner M, Aili Y, King A, Terndrup T, Eivind M, Pannu S, Robart E, Karow S, Hough C, Robinson B, Johnson N, Henning D, Campo M, Gundel S, Seghal S, Katsandres S, Dean S, Khan A, Krol O, Jouzestani M, Huynh P, Weissman A, Yealy D, Scholl D, Adams P, McVerry B, Huang D, Angus D, Schooler J, Moore S, Files C, Miller C, Gibbo K, LaRoze M, Flores L, Koehler L, Morse C, Sanders J, Langford C, Nannini K, MduGalaGaus M, Yeboah P, Morris P, Sturghill J, Self S, C assaulting D, Dhar S, de Wit M, Mason J, Goodwin A, Hall G, Grady A, Chamberlain A, Brown S, Bledsoe J, Leitler P, Leitan I, Starr N, Fergus M, Astron V, Montgomery Q, Smith R, Merritt M, Brown K, Armbruster B, Harris E, Middleton E, Paine R, Johnson S, Barrios M, Eppenstein J, Limkakeng A, McGowan L, Porter T, Bouffier A, Leahy JC, deBoisblanc B, Lamm M, Happel K, Lauto P, Self W, Casey J, Semler M, Collins S, Harel L, Lindell C, Rice T, Stubbe W, Fielder G, Gray C, Johnson J, Roth M, Hays M, Tor D, Zakaria A, Schoenfeld D, Thompson T, Hayden D, Ringwood N, Oldmixon C, Ulyssse C, Morse R, Muzikansky A, Fitzgerald L, Whaiter S, Lagakos A, Brown R, Reineck L, Aggarwal N, Bionrost K, Freemer M, Maclavvich M, Weinmann G, Morrison L, Gillespie M, Kryscio R, Brodie L, Zareba W, Rompalo A, Boechl M, Parsons P, Christie J, Hall J, Horton N, Zolloth L, Dickert N, Diercks D. Effect of hydroxychloroquine on clinical status at 14 days in hospitalized patients with COVID-19: a randomized clinical trial. JAMA. 2020;324(21):2165–76. https://doi.org/10.1001/jama.2020.22240.

28. ACTIV-3/TICO LY-CoV555 Study Group. A neutralizing monoclonal antibody for hospitalized patients with Covid-19. N Engl J Med. 2020;386:1624–32. https://doi.org/10.1056/NEJMoa2033570. 2020;386:1624–32. https://doi.org/10.1056/NEJMoa2033570.

29. Harris PA, Scott KW, Lebo L, Harisan N, Lightner C, Pulley J. ResearchMatch: a national registry to recruit volunteers for clinical research. Acad Med. 2012;87(16):66–73. https://doi.org/10.1097/ACM.0b013e31823b47d2.

30. Pulley JM, Jerome RN, Bernard GR, Olson EJ, Tan J, Wilkins CH, Harris PA. Connecting the public with clinical trial options: the ResearchMatch Trials today tool. J Clin Transl Sci. 2018;2(4):253–7. https://doi.org/10.1016/j.jcts.2018.03.027.

31. Investigational COVID-19 Convalescent Plasma: Guidance for Industry. FDA. 2020. https://www.fda.gov/media/136798/download. Accessed 11 Jan 2021.

32. Bennett M, Yoder S, Brady E, Pulley JM, Roops JD, Stewart TG, Bernard GR, Creech CB, Wheeler AP, Thompson I. A high-throughput liquid bead-array assay confirms strong correlation between SARS-CoV-2 antibody level and COVID-19 severity. Science. 2021;292(5518):765–8. https://doi.org/10.1126/science.abc3182.

33. Case JB, Rohlauf PW, Chen RE, Liu Z, Zhao H, Kim AS, Bloyet LM, Zeng Q, Tahan S, Drot I, Ilagan MXG, Tartell MA, Amarasighe G, Henderson JP, Mensch S, Ustav M, Sidhu S, Virgin HW, Wang D, Ding S, Conti D, Theel ES, Fremont DH, Diamond MS, Whelan SJ. Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2. Cell Host Microbe. 2020;29(2):2165. https://doi.org/10.1016/j.chom.2020.06.021.

34. Zost SJ, Gilchuk P, Chen RE, Case JB, Reidy JX, Trivette A, et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. BioResV. 2020. https://doi.org/10.1101/2020.05.12.001462.

35. WHO R&D Blueprint COVID-19 Therapeutic Trial Synopsis. 2020. https://www.who.int/teams/blueprint/covid-19. Accessed 11 Jan 2021.

36. Self WH, Sennler MW, Leither LM, Casey JD, Angus DC, Brower RG, Chang SY, Collins SP, Eppensteiner JC, Filbin MR, Files DC, Gibbs KW, Ginde AA, Gom MN, Harrell FE Jr, Hayden DL, Hough CL, Johnson NJ, Khan A, Lindsell CJ, Matthay MA, Moss M, Park PK, Rice TW, Robinson BRH, Schoenfeld DA, Shapiro NI, Steingrub JS, Ulysses CA, Weissman A, Yealy DM, Thompson BT, Brown SM, National Heart, Lung, and Blood Institute PETAL Clinical Trials Network, Steingrub JS, Smithline M, Hitz H, Tiriti L, Griesmer C, Thornton-Sommer, S, de Souza L, Hou P, Baron R, Massaro A, Asikis J, Leith E, Sreethala R, Johnsly K, Riker R, Seder D, May T, Baumann M, Eldridge A, Lord C, Shapiro N, Talmor D, O’Ma N, Kirk C, Harrison K, Kurt L, Schermherm M, Banner-Goodspeed V, Boyle K, Dubosh N, Filbin M, Hibbert K, Parny B, Lavrin-Parisons K, Pulido N, Lilley B, Lodesten C, Margolin J, Bratt K, Jones A, Galbraith J, Peacock R, Nandi U, Wachs T, Matthay M, Liu
49. Kelland K. Trial of COVID-19 blood plasma finds no benefit in severely ill patients. Reuters. 2021. https://www.reuters.com/article/us-health-corona-virus-plasma/trial-of-covid-19-blood-plasma-finds-no-benefit-in-severely-ill-patients-idUSKBN29G1JZ.

50. Convalescent Plasma in Outpatients With COVID-19 - ClinicalTrials.gov 2020. https://clinicaltrials.gov/ct2/show/NCT04355767. Accessed 11 Jan 2021.

51. Convalescent Plasma to Limit SARS-CoV-2 Associated Complications - ClinicalTrials.gov 2020. https://clinicaltrials.gov/ct2/show/NCT04373460. Accessed 11 Jan 2021.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.